Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0948265 (
metabolic syndrome
)
24,271
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Erythrocyte deformability (ED) has been scarcely evaluated in obese patients without other concomitant cardiovascular risk factors and contradictory results have been published regarding the influence of plasma lipids on the erythrocyte membrane lipid composition and insulin resistance on this rheological parameter. In 67 severe or morbid obese patients without other cardiovascular risk factors (51 women and 11 men, aged 34+/-11 years) and in 67 controls (45 women and 22 men, aged 32+/-10 years), ED has been determined by ektacytometric techniques in a Rheodyn
SSD
, the elongation index (EI) being measured at 12, 30 and 60 Pa, along with plasma lipids, red blood cell membrane lipids (cholesterol and phospholipids) and insulin resistance indexes in basal conditions and after a three month diet period. No significant differences were obtained in the EI between obese patients and the control group at any of the shear stresses tested (P>0.05). The cholesterol and phospholipid content of the red blood cell membrane did not significantly differ between cases and controls (P>0.05). Obese patients with
metabolic syndrome
showed lower EI at 30 and 60 Pa than those without
metabolic syndrome
(P=0.014 and P=0.031 respectively). Weight loss was not accompanied by any changes in these rheological parameters. Obesity itself does not seem to modify ED. However,
metabolic syndrome
seems to decrease ED, possibly through insulin resistance.
...
PMID:Erythrocyte deformability in obesity measured by ektacytometric techniques. 1772 51
In many epidemiological studies, the relationship between
metabolic syndrome
and the development of congestive heart failure has been established. Due to the latter, an increased interest has been noticed in scientific studies about the changes in the function of the heart in patients with
metabolic syndrome
and possible disturbance mechanisms of the pumping function of the heart in this group of patients. In our research, 120 patients with
metabolic syndrome
and 20 health individuals were studied. The cardiac functions were assessed with the ultrasound imaging machine "Aloka
SSD
5000" (Japan) convex sensor of frequency 3.5 MHz with generally used methods. In the course of the experiment, in patients with MS, concentric hypertrophy of the heart and disturbance of the diastolic function of the heart was noticed. Also it was set that there was a significant correlation between the indexes, which in a superlative degree demonstrate abdominal obesity (WHR) and the indexes of LV hypertrophy during diastole (r = 0.72; P < 0.001), LVM (r = 0.81; P < 0.001) and LA (r = 0.63; P < 0.001).
...
PMID:Particular features of systolic and diastolic functions in patients with metabolic syndrome. 1996 May 86
The contribution of hemorheological alterations in the prothrombotic condition in patients with
metabolic syndrome
(MS) remains a question of debate. We aimed to determine the association between MS and hemorheological parameters by means of a case-control study in 61 MS patients and 89 controls without MS. We determined blood viscosity at 230 s(-1) (Brookfield DVIII viscosimeter); plasma viscosity (Fresenius capillary plasma viscosimeter); erythrocyte aggregation at stasis and 3 s(-1) (MA-1 erythrocyte aggregometer); erythrocyte deformability (Rheodyn
SSD
at shear stresses of 12, 30 and 60 Pascals) and fibrinogen, along with anthropometric, lipidic and inflammatory parameters. MS patients showed increased blood viscosity (p = 0.018), plasma viscosity (p < 0.001), fibrinogen (p < 0.001), erythrocyte aggregation (p < 0.001), and decreased erythrocyte deformability (p = 0.033). In the multivariate regression analysis, fibrinogen and triglycerides predicted plasma viscosity and erythrocyte aggregability, whereas erythrocyte deformability was associated with alterations in the hydrocarbonate metabolism. Blood viscosity related to abdominal obesity. The logistic regression analysis revealed that of all the MS components, only hypertriglyceridemia independently predicts plasma hyperviscosity (OR 3.75 CI 1.44-9.77 p = 0.007) and erythrocyte hyperaggregability (OR 2.41 CI 1.00-5.80 p = 0.050). Erythrocyte hyperaggregability (EA > 8.23) and hyperfibrinogenemia (fibrinogen > 358 mg/dL) were independent predictors of MS: OR 3.34, 95% CI 1.40-7.93, p = 0.006 and OR 2.42 95% CI 1.04-5.66, p = 0.041, respectively. We conclude that MS is associated with an altered hemorheological profile related to inflammatory, lipidic and glucose intolerance parameters which could favor the development of thrombo-embolic and athero-thrombotic events in MS patients.
...
PMID:Association between hemorheological alterations and metabolic syndrome. 2221 20